| The electrostatic landscape of MHC-peptide binding revealed using inception networks E Wilson, JK Cava, D Chowell, R Raja, KK Mangalaparthi, A Pandey, ... Cell Systems 15 (4), 362-373. e7, 2024 | 2 | 2024 |
| An immunogenetic basis for lung cancer risk C Krishna, A Tervi, M Saffern, EA Wilson, SK Yoo, N Mars, V Roudko, ... Science 383 (6685), eadi3808, 2024 | | 2024 |
| Validation of a Machine Learning Model to Predict Immunotherapy Response in Head and Neck Squamous Cell Carcinoma AS Lee, C Valero, S Yoo, JL Vos, D Chowell, LGT Morris Cancers 16 (1), 175, 2023 | | 2023 |
| Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma C Valero, M Golkaram, JL Vos, B Xu, C Fitzgerald, M Lee, S Kaplan, ... The Journal of Clinical Investigation 133 (19), 2023 | 5 | 2023 |
| Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors L Zapata, G Caravagna, MJ Williams, E Lakatos, K AbdulJabbar, ... Nature Genetics, 1-10, 2023 | 20 | 2023 |
| NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer B Salomé, JP Sfakianos, D Ranti, J Daza, C Bieber, A Charap, C Hammer, ... Cancer Cell 40 (9), 1027-1043. e9, 2022 | 51 | 2022 |
| Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity X Ma, N Riaz, RM Samstein, M Lee, V Makarov, C Valero, D Chowell, ... Nature Genetics, 1-17, 2022 | 38 | 2022 |
| A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell Renal Cell Carcinoma PM Rappold, L Vuong, J Leibold, NH Chakiryan, M Curry, F Kuo, E Sabio, ... Cancer Discovery, 2022 | 14 | 2022 |
| Tumor mutational load TA Chan, DC Puente, RM Samstein, L Morris US Patent 11,230,599, 2022 | 2 | 2022 |
| Improved prediction of immune checkpoint blockade efficacy across multiple cancer types D Chowell, SK Yoo, C Valero, A Pastore, C Krishna, M Lee, D Hoen, ... Nature Biotechnology, 1-8, 2021 | 149 | 2021 |
| Pharmacologic modulation of RNA splicing enhances anti-tumor immunity SX Lu, E De Neef, JD Thomas, E Sabio, B Rousseau, M Gigoux, DA Knorr, ... Cell 184 (15), 4032-4047. e31, 2021 | 159 | 2021 |
| Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy C Krishna, RG DiNatale, F Kuo, RM Srivastava, L Vuong, D Chowell, ... Cancer Cell 39 (5), 662-677. e6, 2021 | 211 | 2021 |
| Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: an emerging entity with variable clinical course RG DiNatale, AN Gorelick, V Makarov, KA Blum, AW Silagy, B Freeman, ... European Urology Focus 7 (2), 381-389, 2021 | 33 | 2021 |
| Genetic and environmental determinants of human TCR repertoire diversity C Krishna, D Chowell, M Gönen, Y Elhanati, TA Chan Immunity & Ageing 17 (1), 1-7, 2020 | 55 | 2020 |
| Predicting HLA-I peptide immunogenicity with deep learning and molecular dynamics J Weber, D Chowell, C Krishna, T Chan, R Zhou | 3 | 2020 |
| Sustainable social distancing through facemask use and testing during the Covid-19 pandemic D Chowell, K Roosa, R Dhillon, G Chowell, D Srikrishna medRxiv, 2020 | 5 | 2020 |
| The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype LGT Morris, M Linxweiler, F Kuo, N Katabi, Z Nadeem, MG Dalin, ... Clinical Cancer Research, 2020 | 89 | 2020 |
| Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop D Bedognetti, M Ceccarelli, L Galluzzi, R Lu, K Palucka, J Samayoa, ... Journal for immunotherapy of cancer 7 (1), 1-23, 2019 | 78 | 2019 |
| Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy D Chowell, C Krishna, F Pierini, V Makarov, NA Rizvi, F Kuo, LGT Morris, ... Nature medicine 25 (11), 1715-1720, 2019 | 237 | 2019 |
| Immunogenic neoantigens derived from gene fusions stimulate T cell responses W Yang, KW Lee, RM Srivastava, F Kuo, C Krishna, D Chowell, ... Nature medicine 25 (5), 767-775, 2019 | 314 | 2019 |
